SEP 8, 2026 · JOURNAL ARTICLE
External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy
European Journal of Nuclear Medicine and Molecular Imaging
External validation of an established prognostic score in an independent cohort, demonstrating reproducibility of risk stratification and survival prediction with robust performance metrics, but not introducing new clinical intervention or changing treatment selection.
Important Confirmatory EvidenceProstate Cancer Treatment and ResearchPhilipp KrausewitzProstate Cancer Diagnosis and Treatment
Reported
Median OS (BRS 0)24.0 months
Median OS (BRS 1)15.8 months
Median OS (BRS 2)11.2 months